Ryan D. Cassaday,MD- Physician-Fred Hutch
Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the debate between inotuzumab and blinatumumab to choosing between seat belts and airbags, highlighting his belief that both treatments have significant roles to play. Dr. Cassaday focuses on presenting data supporting inotuzumab, specifically in the context of older adults with pH-negative B cell acute lymphoblastic leukemia (ALL). He discusses studies from MD Anderson and the German Cooperative Group that showcase the effectiveness of inotuzumab in inducing morphologic remission and achieving favorable survival curves, despite challenges such as toxicity.
The presentation, led by Dr. Cassaday, also touches on the incorporation of blinatumumab into treatment regimens, citing evolving perspectives on its use and the impressive results among a selected subgroup of patients.